The medical treatment of non-toxic goiter: several questions remain.
In this review it is concluded that thyroxine (T4), triiodothyronine (T3) and iodine (KI), singly or in combination, are all effective in reducing the goiter size, but there is insufficient evidence to prove which is the best (possibly the combination of T4 + KI?). Higher doses are more effective than smaller, but also lead to more side-effects. Thus, the optimal dose has yet to be found. The suppression of the pituitary thyroid axis plays a major role in the treatment of non-toxic goiter, but it is not definite that this is the only mechanism responsible for the beneficial effect of the agents mentioned. In view of the lack of better evidence, it is simply suggested that non-toxic goiters in young persons should be initially treated aggressively with 200 micrograms of T4/day or more for some months. If the goiter shrinks then the dose should be gradually decreased. If the goiter persists, it is futile to continue with large doses for more than 6-12 months. One may continue with smaller doses, maintaining the serum TSH in the low-normal range. The treatment of benign thyroid nodules with thyroxine is controversial. Probably thyroxine is beneficial in about a third of the cases. For both non-toxic goiters and nodules, autonomy should be excluded before starting thyroxine treatment, and old age, cardiac disease and a poor general condition are contraindications.
Koutras
D A
DA
University of Athens, Department of Clinical Therapeutics, Greece.
D004359:Drug Therapy, Combination; D006044:Goiter, Nodular / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007455:Iodine / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D013974:Thyroxine / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D014284:Triiodothyronine / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*
D014284:Triiodothyronine; D007455:Iodine; D013974:Thyroxine